Next Gleevec Showdown Is Oct. 8
This article was originally published in PharmAsia News
Executive Summary
EDITOR’S PICK â€" Novartis has an Oct. 8 hearing before India’s Madras High Court to argue that the former head of the Indian Patent Office should be disqualified from considering the company’s appeal of a patent rejection for oncologic Gleevec (imatinib), according to The Economic Times of India